Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 19/20 | 0.59 |
| ▸ | KCNJ11 | Q14654 | 19/20 | 0.59 |
| ▸ | ABCC8 | Q09428 | 6/20 | 0.48 |
| ▸ | KCNJ8 | Q15842 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148558 | 0.89 | ABCC9 (0.64) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7149534 | 0.88 | ABCC9 (0.57) | ABCC9KCNJ11ABCC8KCNJ8KDM4E | |
| SCHEMBL5075084 | 0.81 | ABCC9 (0.64) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL5073099 | 0.80 | ABCC9 (0.73) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7149169 | 0.78 | KDM4E (0.48) | ABCC9KCNJ11ABCC8KCNJ8KDM4E | |
| SCHEMBL5075485 | 0.76 | ABCC9 (0.68) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7145540 | 0.74 | ABCC9 (0.61) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7148311 | 0.74 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7147032 | 0.74 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7153511 | 0.74 | ABCC9 (0.76) | ABCC9KCNJ11ABCC8KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632418-B2 | Therapy for asthma, sexual disorders, hypotensive agents, analgesics | ABBOTT LABORATORIES | 2003-10-14 | — | — | US | disclosed |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | ABBOTT LABORATORIES | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | KCNN3, KCNN1, KCNN2 | ABCC9 512/4885KCNJ11 47/4885ABCC8 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.